- Home
- STAA vs XERS Comparison
STAA vs XERS Comparison
Compare STAA & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STAA | XERS |
|---|---|---|
| Founded | 1982 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.9M | 965.6M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | STAA | XERS |
|---|---|---|
| Price | $17.45 | $5.48 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $22.19 | $10.83 |
| AVG Volume (30 Days) | 1.2M | ★ 2.1M |
| Earning Date | 03-03-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $239,442,000.00 | $49,590,000.00 |
| Revenue This Year | $33.83 | $28.65 |
| Revenue Next Year | $8.16 | $18.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $14.69 | $3.81 |
| 52 Week High | $30.81 | $10.08 |
Technical Indicators
Market Signals| Indicator | STAA | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 43.95 | 31.07 |
| Support Level | $17.13 | $4.30 |
| Resistance Level | $18.19 | $5.49 |
| Average True Range (ATR) | 0.96 | 0.30 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 22.26 | 6.53 |
Price Performance
Historical ComparisonAbout STAA STAAR Surgical Company
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.